RayKnowChina Research Map
Shortlist0

Foshan

First People's Hospital of Foshan

佛山市第一人民医院

Listed for 5 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First People's Hospital of Foshan

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌6 papers led
  2. Osteosarcoma骨肉瘤1 paper led
  3. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  4. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病0 papers led
  5. IgA nephropathyIgA 肾病2 papers led

Not listed for: Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 6 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
8
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 222025

2 hospitals in Foshan for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07661771

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChangsha, Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan

  2. Recruiting
    QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06749899

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan

  3. Recruiting
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06239727

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang

  4. Recruiting
    TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06301165

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesDongguan, Foshan, Guangzhou, Shenzhen, Wuhan

  5. Recruiting
    GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06455410

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 7 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen

  6. Recruiting
    Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2021-03
    Registry
    NCT04778956

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesFoshan, Guangzhou, Zhongshan

  7. Recruiting
    Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
    Phase
    N/A
    Started
    2017-10
    Registry
    NCT03353467

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFoshan, Guangzhou, Nanning, Zhongshan

  8. Not yet recruiting
    Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity
    Phase
    Phase 3
    Started
    2025-08
    Registry
    NCT07072000

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Wuzhou, Zhanjiang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AIRadiotherapy techniqueSide effects & quality of life
Departments in papersRadiology / nuclear medicineRadiation oncologyENT / head & neck surgery
Papers it led6
  1. Evaluation of radiation induced brain injury in nasopharyngeal carcinoma patients based on multi-parameter quantitative MRI: A prospective longitudinal study.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  2. A dataset of primary nasopharyngeal carcinoma MRI with multi-modalities segmentation.2025Scientific dataFree full text
  3. MFNet: Meta-learning based on frequency-space mix for MRI segmentation in nasopharyngeal carcinoma.2024Journal of cellular and molecular medicineFree full text
  4. Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngeal carcinoma.2023Frontiers in immunologyFree full text
  5. MRI-based radiomics models can improve prognosis prediction for nasopharyngeal carcinoma with neoadjuvant chemotherapy.2022Magnetic resonance imaging
  6. Usefulness of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography combined with the platelet-lymphocyte ratio in predicting the prognosis of nasopharyngeal carcinoma.2022The British journal of radiologyFree full text
All its trials on ClinicalTrials.gov, any status14
  1. Study of Neoadjuvant Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT01417390Lead sponsorPhase 2Start 2011-11
  2. Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal CarcinomaRecruitingNCT07661771Study sitePhase 3Start 2026-07
  3. Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal CavityNot yet recruitingNCT07072000Study sitePhase 3Start 2025-08
  4. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  5. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03
  6. GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06455410Study sitePhase 2Start 2024-06
  7. TPC Versus GP Induction Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06301165Study sitePhase 2Start 2024-03
  8. Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal CarcinomaRecruitingNCT04778956Study sitePhase 3Start 2021-03
  9. Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma PatientsRecruitingNCT03353467Study siteN/AStart 2017-10
  10. PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaActive, not recruitingNCT04907370Study sitePhase 3Start 2021-08
  11. Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent ChemoradiotherapyActive, not recruitingNCT04384627Study sitePhase 3Start 2019-12
  12. PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT03427827Study sitePhase 3Start 2018-07
  13. Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03700476Study sitePhase 3Start 2018-12
  14. Endostar for Locally Recurrent Nasopharyngeal CarcinomaStatus unknownNCT02636231Study sitePhase 2Start 2015-11
More papers found outside PubMed (not counted)22
  1. A Deep-Learning Model Integrating Multi-Modality Data for Predicting the Recurrence of Nasopharyngeal Carcinoma2025International Journal of Radiation Oncology*Biology*Physicsarticle
  2. A Novel Mamba-Based 3D Dose Prediction Model with Channel-Aware Scan for Nasopharyngeal Carcinoma Radiotherapy2025International Journal of Radiation Oncology*Biology*Physicsarticle
  3. Abstract 4686: Efficacy and safety of efbemalenograstim alfa as primary prophylaxisfor concurrent chemo-radiotherapy induced neutropenia2025Cancer Researchconference-abstract
  4. Dynamic circulating tumor DNA-driven, risk-adapted systematic therapy in nasopharyngeal carcinoma: The EP-STAR trial.2025Journal of Clinical Oncologyconference-abstract
  5. LBA35 Iza-Bren (BL-B01D1), an EGFR×HER3 bispecific antibody-drug conjugate, versus physician's choice of chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma: A randomized, open-label, multicenter, phase III, piv2025Annals of Oncologyconference-abstract
  6. Novel genetic algorithm‐based individual treatment effect scoring model for optimizing decision‐making: Induction chemotherapy in nasopharyngeal carcinoma2025Open Research (University of Surrey)article
  7. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncologyarticle
  8. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncologyconference-abstract
  9. Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.2024Journal of Clinical Oncologyconference-abstract
  10. Analysis of proliferating Treg cells as a predictor for immunotherapy response using systemic longitudinal immune profiling: Biomarker analysis of the phase 3 CONTINUUM trial.2024Journal of Clinical Oncologyconference-abstract
  11. PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncologyconference-abstract
  12. Prognostic Value of Parapharyngeal Involvement Subclassifications Divided by Parapharyngeal Muscles in Nasopharyngeal Carcinoma: A Study of 1752 Patients from Two Centers2024Research Squarepreprint
  13. Radiotherapy Target Volume Delineation Based on Post-Induction Chemotherapy Gross Tumor Volume vs. Pre-Induction Volume for Locoregionally Advanced Nasopharyngeal Carcinoma: An Open-label, Non-Inferiority, Multicenter, Randomized Phase III 2024International Journal of Radiation Oncology*Biology*Physicsarticle
  14. Radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy in patients with low-risk nasopharyngeal carcinoma: Updated results from a multicenter, open-label, non-inferiority, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  15. The efficacy and safety of ulinastatin in the prevention and treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A multicenter, open-label, randomized controlled clinical trial.2024Journal of Clinical Oncologyconference-abstract
  16. PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)2023Journal of Clinical Oncologyconference-abstract
  17. Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, noninferiority, randomised phase III trial.2022Journal of Clinical Oncologyconference-abstract
  18. Sparing Irradiation vs. Conventional Irradiation to the Medial Retropharyngeal Space in Patients with Nasopharyngeal Carcinoma: An Open-Label, Non-Inferiority, Multicenter, Randomized Phase III Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  19. 859O Refining TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma: A multicenter cohort study2021Annals of Oncologyarticle
  20. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncologyconference-abstract
  21. The radiomics features could be used to predict the distinct metastases in nasopharyngeal carcinoma patients2021Research Squarepreprint
  22. [Retracted] miR-663b promotes tumor cell proliferation, migration and invasion in nasopharyngeal carcinoma through targeting TUSC22021Experimental and Therapeutic Medicinearticle

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

5 hospitals in Foshan for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Foshan for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersClinical trials / research unit

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led no English-language PubMed papers on lymphangioleiomyomatosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Foshan for lymphangioleiomyomatosis28 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicine
Chinese-language papers (not in the count)1
  1. [Incidental lymphangioleiomyomatosis in pelvic-celiac lymph nodes of gynecological pelvic malignant tumors: a clinicopathological study of 3 cases].2022Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

1 hospital in Foshan for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

佛山市第一人民医院

First People's Hospital of Foshan

佛山

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
First People's Hospital of Foshan Affiliated to Sun Yat-sen University; Foshan First People's Hospital; Tumor Hospital of First People's Hospital of Foshan; First People's Hospital of FoShan; First People'S Hospital of Foshan City

Suggest a correctionDownload the data